Fresenius acquires Hema Metrics' Crit-Line monitoring products
This article was originally published in Clinica
Dialysis specialist Fresenius Medical Care has acquired Hema Metrics’ Crit-Line system, a noninvasive patient monitoring tool. The deal, which is already closed, is worth up to $25m; $12m was paid upfront and the remainder will be paid as milestones between now and 2016. The device uses photo-optical technology to measure blood parameters including haematocrit, percent blood volume change, and continuous oxygen saturation; monitoring these can help clinicians improve fluid management during haemodialysis and manage anaemia. Bad Homburg, Germany-based Fresenius described the technology as an “excellent fit” with its 2008K, 2008K2 and 2008T dialysis machines, and hopes to make Crit-Line the standard of care for fluid and anaemia management in North America. Crit-Line received 510(k) clearance from the US FDA in October 2010, and is also CE marked for sale in Europe. Chronic kidney failure affects about 1.9 million people worldwide.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.